House Ag Committee Says ‘No’ to GMO Labeling, What’s Next? by Katherine Paul

With no debate and only a voice vote, the U.S. House of Representatives Committee on Agriculture today (July 14, 2015) passed out of committeeH.R. 1599, a bill to preempt states’ rights to label GMOs. Within hours, it was announced that the bill will go straight to the House floor, as early as next week, with no vote in the Energy and Commerce Committee.

If we don’t stop it in the House next week, the fight to stop this “Mother of All Monsanto Protection Acts” will take place next in the U.S. Senate, by early fall. In his opening statement this morning, Committee Chairman Rep. K. Michael Conaway (R-Texas) (who shortly after today’s vote said he will co-sponsor H.R. 1599) couldn’t have sounded more like a Monsanto employee if he’d tried. Conaway nailed the biotech industry’s favorite talking points and mistruths, beginning with this one:

In testimony before this Committee, multiple representatives of the food and agricultural sectors commented on the cost burden that would be placed on our food system if we were to allow the 50 States, more than 3000 counties and nearly 20,000 towns and cities in the United States to establish their own laws regulating interstate commerce.

Time and again, independent experts have stated that the cost of labeling GMO foods and ingredients, to manufacturers, retailers and consumers, would be negligible here in the U.S., just as it has been in the more than 60 countries that already require labeling. GMO labels are costless, as pointed out in this Washington Post article. Companies regularly update their food packaging as they come up with new designs or marketing strategies.

And then there was the ultimate lie about GMOs, that they have been “proven safe:”

We all recognize that the overwhelming consensus within the science community is that these biotech products are safe.  We likewise understand that each and every biotech product in the marketplace today has been reviewed thorough a voluntary food safety consultation process at the Food and Drug Administration.

Read more